The Cancer We Were Taught to Fear May Not Be the Disease We Think It Is

Somewhere in America today, roughly 1,700 people will die of cancer before the sun sets. That is not a statistic from a forgotten decade of medicine. That is not a number frozen in the archives of some pre-antibiotic age when doctors still believed in bloodletting. That is today's number — every single day, in the most medically advanced nation on Earth, seventy people an hour are told that the war inside their bodies has ended, and the enemy has won.

And here is the sentence that should stop every reader cold: what if the war was being fought with the wrong map?

This is not a column about despair. It is a column about a quiet, controversial, and deeply consequential argument now being made by serious scientists — an argument that, if even partially correct, could reshape how humanity understands its most feared disease. I write today not as a doctor, and certainly not as a substitute for one, but as a columnist whose duty is to bring the world's most important conversations to an African readership that too often only hears half the story. So let us talk about cancer — and about a man named Thomas Seyfried.

The Century-Old Assumption

For roughly one hundred years, the reigning theory of cancer has been genetic. The story most of us were raised on goes like this: a cell's DNA suffers damage — from radiation, from chemicals, from bad luck — and that damaged cell begins to multiply out of control. Fix the broken genes, or kill the cells carrying them, and you defeat the cancer. This is the foundation on which trillions of dollars of research, and the entire modern pharmaceutical industry's approach to oncology, has been built.

Thomas Seyfried, a professor of biology at Boston College and author of Cancer as a Metabolic Disease, argues that this foundation is incomplete — and possibly, in crucial respects, wrong. His claim is not that genetics play no role in cancer. His claim is that the deeper origin of the disease lies not in the nucleus of the cell, where DNA resides, but in the mitochondria — the tiny energy-producing structures inside nearly every cell in the human body, the same structures our biology teachers once reduced to a single throwaway line: "the powerhouse of the cell."

Seyfried's argument, stated plainly, is this: healthy cells generate energy primarily through a process called oxidative phosphorylation, which depends on functioning mitochondria and requires oxygen. Cancer cells, however, largely abandon this efficient pathway and instead rely on a cruder, more ancient process called fermentation — the same basic metabolic trick single-celled organisms used billions of years before mitochondria ever existed. Because fermentation is inefficient, cancer cells must gorge themselves on fuel to survive — specifically, according to Seyfried, on two substances: glucose (sugar) and glutamine (an amino acid). Starve a tumor of these two fuels simultaneously, he argues, and you can weaken it far more effectively than genetics-based approaches alone typically manage.

Why This Matters Beyond the Laboratory

If Seyfried is even partially right, several uncomfortable questions follow — questions that deserve public airing, precisely because they are contested.

Why, he asks, do wealthy, industrialized nations suffer far higher cancer rates than poorer nations with far less access to modern medicine? Why do children — whose DNA has had so little time to accumulate the genetic damage that mainstream theory blames — still develop cancer, sometimes in infancy? Why does a diet built around minimizing sugar and stabilizing metabolic markers appear, in some clinical observations, to make chemotherapy and immunotherapy work more effectively rather than less?

These are not settled answers. They are provocations — the kind that responsible science thrives on, and the kind that responsible journalism must present honestly, with all their rough edges intact.

Seyfried and his collaborators have developed what they call the Glucose Ketone Index, a measurement intended to track a patient's metabolic state, and a "press-pulse" therapeutic strategy that combines dietary metabolic restriction with existing treatments rather than replacing them outright. He points to specific, publicized cases — including patients with glioblastoma, one of the most lethal brain cancers known to medicine, surviving years beyond typical prognosis — as evidence worth investigating further.

The Honest Counterargument

Now, let me steel-man the other side, because a columnist who only tells you what is exciting and not what is contested has failed you.

The overwhelming majority of oncologists and cancer researchers worldwide continue to regard cancer as fundamentally a genetic disease, with metabolic changes as a downstream consequence rather than the root cause. The genetic model has produced measurable, life-saving results: targeted therapies, immunotherapies, and precision medicine approaches that have transformed survival rates for cancers that were once uniformly fatal — childhood leukemia being perhaps the most stunning example. Critics of the purely metabolic framing argue that Seyfried's model, while intellectually serious, remains a minority position, has not been validated through the kind of large-scale, randomized clinical trials that would be required to change standard-of-care treatment guidelines, and that dietary interventions like ketogenic protocols — however promising in adjunct — carry real risks if pursued instead of, rather than alongside, evidence-based conventional treatment, especially for malnourished or already-weakened cancer patients.

This tension — between a compelling alternative hypothesis and an entrenched, evidence-heavy mainstream — is precisely what makes this a live scientific debate rather than a closed case. Readers should hold both truths at once: that unconventional theories sometimes turn out to be right, and that "unconventional" alone has never been proof of correctness.

What This Means, Standing in Accra

Bring this conversation home, to Ghana, to Kumasi, to the family compounds where cancer diagnoses still often arrive too late because screening infrastructure remains thin on the ground. Our national cancer burden is shaped less by exotic scientific disputes and more by access — access to early detection, to affordable treatment, to oncologists per capita that remain far below what wealthier nations enjoy.

And yet Seyfried's observation about wealthy nations having disproportionately high cancer rates should give every Ghanaian pause about what "development" truly costs the body. As our diets shift — more refined sugar, more processed foods, more sedentary hours — are we importing not just prosperity, but also the very metabolic conditions this research suggests may fuel tumor growth? That is a conversation our Ministry of Health, our nutritionists, and our churches and mosques — those trusted gathering places where health messages travel faster than any government pamphlet — ought to be having.

A Necessary Caution

I want to be unambiguous about one thing, because irresponsible health journalism has cost lives before: nothing in this column should be read as medical advice, and no reader battling cancer should alter their treatment based on a newspaper column, however well-researched. Seyfried's own published work does not advocate abandoning conventional oncology — it advocates combining metabolic strategies with it, under clinical supervision. Anyone facing a cancer diagnosis owes it to themselves and their families to have this conversation directly with their oncologist, not with a columnist in Accra.

A Chief's Closing Word

I have built this column, and this platform, on a simple conviction: that the African reader deserves the same access to the frontier of global knowledge as any reader in London, New York, or Berlin — and deserves it delivered with both the excitement it warrants and the caution it requires.

Thomas Seyfried may be remembered as a visionary who forced a century-old field to confront its blind spots. Or he may be remembered as a brilliant scientist whose hypothesis, however elegant, did not survive rigorous trial. History has not yet rendered its verdict, and neither should we, prematurely.

But 1,700 deaths a day is not a number that permits complacency, wherever it is happening in the world. If there is even a reasonable chance that our understanding of cancer has been incomplete for a hundred years, then the debate itself — loud, uncomfortable, and unresolved — is worth having in the full light of day.

That, dear reader, is the chief's word for today. Until next time — stay curious, stay skeptical, and stay well.

Chief Tutu Baffour Asare Brownsy Williams is founder of Brownsy Silva Company and an opinion columnist for Modern Ghana, writing on global affairs, science, and culture for African and diaspora readers.